Introduction —
This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Screening for prostate cancer".)
International
●European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG): Guidelines on prostate cancer, update (2024)
●SIOG: Updated recommendations on prostate cancer management in older patients (2019)
●SIOG: A position paper on radiopharmaceuticals in the elderly cancer patient – Practical considerations, with a focus on prostate cancer therapy (2017)
●Society for Immunotherapy of Cancer (SITC): Consensus statement on immunotherapy for the treatment of prostate carcinoma (2016)
Canada
●Choosing Wisely Canada: Don't initiate management in patients with low-risk prostate cancer (T1/T2, PSA <10 ng/mL, and Gleason score <7) without first discussing active surveillance (2024)
●Canadian Urological Association (CUA): Guideline on genetic testing in prostate cancer (2023)
●Ontario Health (OH) (Cancer Care Ontario [CCO]): Endorsement of American Society of Clinical Oncology (ASCO) rapid recommendation on 177Lutetium-prostate-specific membrane antigen-617 (PSMA-617) for metastatic castration-resistant prostate cancer (mCRPC) (2023)
●CUA-Canadian Urologic Oncology Group (CUOG): Guideline for the management of castration-resistant prostate cancer (CRPC), update (2022)
●CUA-CUOG: Guideline on metastatic castration-naive and castration-sensitive prostate cancer, update (2022)
●CUA: Best practice report on bone health in prostate cancer (2021)
●OH (CCO): An endorsement of the ASCO guideline on the initial management of noncastrate advanced, recurrent, or metastatic prostate cancer, update (2021)
●OH (CCO): Multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer (2021)
●CUA: Best practice report on prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer (2021)
●Choosing Wisely Canada: Don't do routine bone scans in men with low-risk prostate cancer (2021)
●British Columbia Guidelines and Protocols Advisory Committee (GPAC): Prostate cancer – Part 1: Diagnosis and referral in primary care (2020)
●British Columbia GPAC: Prostate cancer – Part 2: Follow-up in primary care (2020)
●Choosing Wisely Canada: Don't order a routine bone scan and CT scan of the pelvis in men with low-risk prostate cancer (2020)
●OH (CCO): An endorsement of the American Society for Radiation Oncology (ASTRO), ASCO, and American Urological Association (AUA) evidence-based 2018 guideline on hypofractionated radiation therapy for localized prostate cancer (2020)
●CCO: Biodegradable rectal spacers for prostate cancer radiotherapy (2019)
●ASCO/CCO: Joint guideline on brachytherapy for patients with prostate cancer, update (2017)
●CCO: Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management (2017)
●CCO: Performance of needle biopsy of the prostate for men with suspected or established prostate cancer (2017)
●CCO: Bone health and bone-targeted therapies for prostate cancer (2016)
●CCO: Magnetic resonance imaging for pre-treatment local staging of prostate cancer (2016)
●CCO: Referral of suspected prostate cancer by family physicians and other primary care providers (2016)
●CCO: Follow-up care and psychosocial needs of survivors of prostate cancer (2015)
●ASCO and CCO: Clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer (2014)
●CCO: Active surveillance for the management of localized prostate cancer (2014)
United States
●National Cancer Institute (NCI): Prostate cancer – Health professional version
●American Society of Clinical Oncology (ASCO): Guideline on germline and somatic genomic testing for metastatic prostate cancer (2025)
●US Prostate Cancer Conference (USPCC): Consensus recommendations for implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer, 2024 (published 2025)
●American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO): Guideline on salvage therapy for prostate cancer (2024)
•Part I – Introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy
•Part II – Treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy
•Part III – Salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions
●AUA/Society of Genitourinary Reconstructive Surgeons (GURS)/Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU): Guideline on incontinence after prostate treatment (2019, amended 2024)
●ASCO: Guideline rapid recommendation – Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer (2023)
•ASCO: Rapid recommendation – Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer (2022)
•ASCO and Cancer Care Ontario (CCO): Clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer (2014)
●ASCO: Guideline for initial management of noncastrate advanced, recurrent, or metastatic prostate cancer, update (2023)
●AUA/SUO: Guideline on advanced prostate cancer (2020, amended 2023)
●American College of Radiology (ACR): ACR Appropriateness Criteria on post-treatment follow-up of prostate cancer (2022)
●ACR: ACR Appropriateness Criteria on pretreatment detection, surveillance, and staging of prostate cancer (2022)
●AUA/ASTRO: Guideline on clinically localized prostate cancer (2022)
•Part I – Introduction, risk assessment, staging, and risk-based management
•Part II – Principles of active surveillance, principles of surgery, and follow-up
•Part III – Principles of radiation and future directions
●American Brachytherapy Society (ABS): A systemic review and executive summary of an evidence-based consensus statement on low dose rate brachytherapy for primary treatment of localized prostate cancer (2021)
●ACR-ABS-ASTRO: Practice parameter for transperineal permanent brachytherapy of prostate cancer (2020)
●ASCO: Endorsement of a CCO guideline – Bone health and bone-targeted therapies for prostate cancer (2020)
●ASCO: Guideline on optimum imaging strategies for advanced prostate cancer (2020)
●ASTRO/AUA: Guideline on adjuvant and salvage radiotherapy after prostatectomy, 2018 update (published 2019)
●ASCO: Guideline on molecular biomarkers in localized prostate cancer (2019)
●ASTRO, ASCO, and AUA: Evidence-based guideline on hypofractionated radiation therapy for localized prostate cancer (2018)
●ABS: Practice parameter on combination of brachytherapy and external beam radiation for high-risk prostate cancer (2017)
●ASCO: Provisional clinical opinion on second-line hormonal therapy for men with chemotherapy-naïve, castration-resistant prostate cancer (2017)
●ASCO/CCO: Joint guideline on brachytherapy for patients with prostate cancer, update (2017)
●ABS: Consensus guidelines for high-dose-rate prostate brachytherapy (2012)
●ABS: Consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy (2012)
Europe
●European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG): Guidelines on prostate cancer, update (2024)
●European Society for Medical Oncology (ESMO): Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents (2023)
•ESMO: Clinical practice guidelines for diagnosis, treatment, and follow-up – Prostate cancer (2020)
●ESMO: Consensus conference guidelines on prostate cancer, 2012 (published 2013)
United Kingdom
●National Institute for Health and Care Excellence (NICE): Guideline on prostate cancer – Diagnosis and management (2019, updated 2021)
●NICE: Quality standard on prostate cancer (2015, updated 2021)
India
●Indian Council of Medical Research (ICMR): Consensus document for management of prostate cancer (2023)
●Chinese Society of Clinical Oncology (CSCO), Indian Society of Medical and Paediatric Oncology (ISMPO), Japanese Society of Medical Oncology (JSMO), Korean Society for Medical Oncology (KSMO), Malaysian Oncological Society (MOS), Singapore Society of Oncology (SSO), and Taiwan Oncology Society (TOS): Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer (2022)
Australia–New Zealand
●Royal Australian College of General Practitioners (RACGP): Guidelines for preventive activities in general practice – Prostate cancer, 10th edition (2024)
●Choosing Wisely Australia: Do not proceed with any treatment for localised prostate cancer unless the man has been offered a consultation with a urologist and a radiation oncologist, and taken time to consider the advantages and disadvantages of each treatment option (2022)
●Cancer Australia: Optimal care pathway for men with prostate cancer, second edition (2021)
●Choosing Wisely Australia: Don't initiate management of low risk prostate cancer without discussing active surveillance (2021)
●Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG): Recommendations on radiotherapy for node-positive prostate cancer (2019)
●Australian and New Zealand FROGG: Recommendations on radiotherapy for recurrent prostate cancer (2018)
●Prostate Cancer Working Group and Ministry of Health: Guidance on using active surveillance to manage men with low-risk prostate cancer (2015)
●Prostate Cancer Working Group and Ministry of Health: Prostate cancer management and referral guidance (2015)
●Prostate Cancer Taskforce: Diagnosis and management of prostate cancer in New Zealand men – Recommendations (2013)
Japan
●[In English] Japanese Urological Association (JUA): Japanese clinical practice guidelines for prostate cancer, fourth edition (2023)
●[In English] Chinese Society of Clinical Oncology (CSCO), Indian Society of Medical and Paediatric Oncology (ISMPO), Japanese Society of Medical Oncology (JSMO), Korean Society for Medical Oncology (KSMO), Malaysian Oncological Society (MOS), Singapore Society of Oncology (SSO), and Taiwan Oncology Society (TOS): Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer (2022)
●[In Japanese] Choosing Wisely Japan: Low-risk prostate cancer – Do not rush into treatment (2016)
